Similar Papers

Paper Title
Journal
Date
Author
The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy
Gloria Iacoboni ... Juan Luis Reguera
Blood | VOL. 142
Gloria Iacoboni, et. al.Gloria Iacoboni ... Juan Luis Reguera
28 Nov 2023
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
Paolo Strati ...
Blood Advances | VOL. 4
Paolo Strati, et. al.Paolo Strati ...
25 Aug 2020
High first trimester ferritin levels differ according to parity and are independently related to preterm birth: A prospective cohort study.
Annabel Broekhuis ... Steven V Koenen
Acta obstetricia et gynecologica Scandinavica | VOL. 103
Annabel Broekhuis, et. al.Annabel Broekhuis ... Steven V Koenen
22 Apr 2024
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients
Jaromir Tomasik ... Grzegorz Władysław Basak
Expert opinion on biological therapy | VOL. ahead-of-print
Jaromir Tomasik, et. al.Jaromir Tomasik ... Grzegorz Władysław Basak
03 May 2024
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma.
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.